Sistema complementario

MASP2 Protein, Mouse, Recombinant (His) is expressed in E.

LEP(116-130)(mouse) is a synthetic leptin peptide fragment.

BCX 1470 inhibits factor D & C1s better than trypsin (IC50: 96 nM & 1.6 nM, 3.4- & 200-fold).

Avacopan (CCX168) is a C5aR antagonist with selective and oral activity. Avacopan can be used to treat ANCA-related vasculitis. Cost-effective and quality-assured.

Leukadherin-1 boosts CD11b/CD18 adhesion, lowers leukocyte movement, cuts inflammation.

PMX-53 is a potent and orally active CD88 (C5aR) antagonist (IC50: 20 nM) and inhibits C5a-induced neutrophil myeloperoxidase release and chemotaxis with IC50

C3a 70-77 2TFA(63555-63-5(free base)) (Complement 3a (70-77)) is an octapeptide corresponding to the COOH terminus of C3a.

ADH-503 (GB1275) is an orally available, allosteric CD11b small molecule agonist.Cost-effective and quality-assured.

Complement factor D-IN-2 is an inhibitor of Complement factor D and reduces the excessive activation of complement factor D.

Eculizumab is a recombinant humanized monoclonal antibody against the complement protein C5

Danicopan (ACH-4471), an oral factor D inhibitor, binds strongly (Kd 0.54 nM) and may treat PNH and aHUS.

JR14a (5-(Bis(4-chlorophenyl)methyl)-3-methylthiophene-2-carbonyl)-l-arginine hydrochloride) is a potent antagonist of human complement C3a receptor.

TLQP 21 acetate: Agonist for C3aR1, EC50 - 10.3 μM (mouse), 68.8 μM (human); VGF-derived with endo/extraendocrine traits.

Compstatin control peptide acetate is an inhibitor of complement protein C3 by binding and inhibiting the cleavage of complement C3.

Iptacopan hydrochloride (LNP023 hydrochloride) is an orally bioavailable, highly potent and highly selective factor B inhibitor with an IC50 of 10 nM.

AMY-101 acetate (Cp40 acetate) is a peptide, an inhibitor of C3 Complement in gingivitis and periodontitis, reduces inflammation and lowers MMP-8 and MMP-9.

Complement C5 Protein, Human, Recombinant (Complement C5a) is expressed in E.

Complement C3 Protein, Bovine, Recombinant (His & SUMO) is expressed in E.

Derived from proteolytic degradation of complement C5, C5a anaphylatoxin is a mediator of local inflammatory process.

Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate

C1QA Protein, Human, Recombinant (His & Myc) is expressed in E. coli.

Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.

C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system.

C8 is a constituent of the membrane attack complex.

Factor D cleaves factor B when the latter is complexed with factor C3b, activating the C3bbb complex, which then becomes the C3 convertase of the alternate

Expression system: E. coli
Length: 306-351, Partial
Activity: Not Tested

A positive regulator of the alternate pathway of complement.

Expression system: E. coli
Length: 41-234, Partial
Activity: Not Tested

Expression system: E. coli
Length: 306-351, Partial
Activity: Not Tested

A positive regulator of the alternate pathway of complement.

Complement C3 Protein, Mouse, Recombinant (His & SUMO) is expressed in E.

C1r B chain is a serine protease that combines with C1q and C1s to form C1, the first component of the classical pathway of the complement system.

Non-enzymatic component of C3 and C5 convertases and thus essential for the propagation of the classical complement pathway.

Receptor for the chemotactic and inflammatory peptide anaphylatoxin C5a.

May regulate the number of excitatory synapses that are formed on hippocampus neurons. Has no effect on inhibitory synapses.

Complement C4-B Protein, Human, Recombinant (His & SUMO) is expressed in E. coli.

May regulate the number of excitatory synapses that are formed on hippocampus neurons.

Constituent of the membrane attack complex (MAC) that plays a key role in the innate and adaptive immune response by forming pores in the plasma membrane of

Complement C8a Protein, Human, Recombinant (His) is expressed in E. coli.

Factor B which is part of the alternate pathway of the complement system is cleaved by factor D into 2 fragments: Ba and Bb.

C1q associates with the proenzymes C1r and C1s to yield C1, the first component of the serum complement system.

Complement C5 Protein, Rat, Recombinant (His & Myc) is expressed in E.

Complement factor I Protein, Rat, Recombinant (His & Myc) is expressed in Baculovirus insect cells with N-10xHis and C-Myc tag.

C1s B chain is a serine protease that combines with C1q and C1r to form C1, the first component of the classical pathway of the complement system.

Empasiprubart (anti-C2 mAb) inhibits classical & lectin complement pathways upstream of C3, showing efficacy in autoimmune models.

NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist.

C5aR-IN-2, a potent C5aR inhibitor, shows promise for researching inflammatory diseases.

Isocyclosporin A is a rearranged degradation product. It is formed by acid treatment of cyclosporin A under aqueous and non-aqueous conditions.

BCX 1470 inhibits the esterolytic activity of factor D and C1s (IC50: 96 nM and 1.6 nM), 3.4- and 200-fold better than that of trypsin, respectively.

FD-IN-1 is an orally active Factor D (FD) inhibitor (IC50=12 nM), inhibits Factor XIa and Tryptase β2 with IC50 values of 7.7 and 6.5 μM, respectively.

Complement C5-IN-1 is a small-molecule inhibitor of complement component 5 protein (C5).

NDT 9513727 is a potent, selective and competitive C5aR1 inverse agonist for the study of inflammatory and immune disorders.

EG00229 blocks VEGF-A/NRP1 binding, IC50 of 3 μM; doesn't affect VEGFR-1/2. It's an NRP1 antagonist.

Factor D inhibitor 6 is a potent, highly selective, and orally active compound that specifically inhibits the activity of factor D (FD) with an IC50 of 30 nM and a Kd of 6 nM. It does not exhibit inhibitory effects against factor B, classical and lectin complement-pathway activation, or a broad array of receptors, ion channels, kinases, and proteases.

Factor B-IN-2 is a potent inhibitor (IC50: 1.5 μM) of complement factor B. Factor B-IN-2 can be used to study inflammatory and immune-related diseases.

W-54011: potent non-peptide C5a receptor blocker; binds 125I-C5a (Ki=2.2nM); stops Ca2+ movement, chemotaxis, ROS in neutrophils (IC50=1.6-3.1nM).

EG01377 is a NRP1 antagonist with antiangiogenic, antimigratory, and antitumor activity, Kd 1.32 μM, IC50s 609 nM for NRP1-a1/b1, inactive on NRP2.

C5aR-IN-1, a potent C5aR inhibitor, may aid in researching autoimmune and inflammatory diseases.

Iptacopan (LNP023) is an inhibitor with high affinity to factor B, with a KD value of 7.9 nM and an IC50 value of 10 nM. Cost-effective and quality-assured.

Pelecopan (BCX9930), an oral complement factor D inhibitor, prevents hemolysis in PNH (IC50=14.3 nM).

(Rel)-Factor B-IN-5 is a complement factor B inhibitor that can be used to study diseases associated with activation of the alternative complement pathway.

Factor B-IN-4 is a potent inhibitor (IC50: 1 μM) of complement factor B. Factor B-IN-4 can be used to study inflammatory and immune-related diseases.

Factor B-IN-3 is a potent inhibitor of complement factor B. Factor B-IN-3 can be used to study inflammatory and immune-related diseases.

Izicopan (INF056) is an antagonist of the complement factor C5a receptor. It inhibits C5a-induced calcium mobilization with an IC50 ranging from 10 to 100 nM.

Refinicopan is a complement factor D inhibitor with an IC50 of 10 nM, demonstrating an inhibition activity on rabbit erythrocyte hemolysis with an IC50 of 41 nM. It possesses excellent pharmacokinetic and pharmacodynamic properties.

4-Octylphenol is an endocrine disruptor with gender-specific effects on male germ cells, significantly reducing the mitotic index and the number of spermatogonia. It also causes inflammatory damage in the gills of carp by activating the complement system through the C3a/C3a receptor (C3a/C3aR) axis and C5a/C5a receptor 1 (C5a/C5aR1) axis. Furthermore, 4-Octylphenol induces immune suppression by disrupting the balance between helper T (Th) cells 1/Th2 and regulatory T (Treg)/Th17 cells, and triggers inflammatory damage through the Toll-like receptor 7 (Toll-like Receptor (TLR))/inhibitor κBα/nuclear factor κB (TLR7/IκBα/NF-κB) pathway.

Factor B-IN-6 is an orally bioavailable inhibitor of Factor B. It exhibits significant inhibitory activity on the activation of the human serum alternative pathway. In model animals, Factor B-IN-6 can improve kidney lesions and function, reducing urinary protein levels. Factor B-IN-6 is applicable for kidney disease research.

C5aR-IN-3, a potent C5aR inhibitor, may treat autoimmune and inflammatory diseases.